Tempest Therapeutics, Inc. – NASDAQ:TPST

Tempest Therapeutics stock price today

$9.17
+8.32
+990.37%
Financial Health
0
1
2
3
4
5
6
7
8
9

Tempest Therapeutics stock price monthly change

-62.29%
month

Tempest Therapeutics stock price quarterly change

-62.29%
quarter

Tempest Therapeutics stock price yearly change

-82.80%
year

Tempest Therapeutics key metrics

Market Cap
33.42M
Enterprise value
20.58M
P/E
-1.08
EV/Sales
N/A
EV/EBITDA
-0.41
Price/Sales
N/A
Price/Book
2.21
PEG ratio
-0.03
EPS
-1.73
Revenue
N/A
EBITDA
-29.13M
Income
-29.75M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Tempest Therapeutics stock price history

Tempest Therapeutics stock forecast

Tempest Therapeutics financial statements

Tempest Therapeutics, Inc. (NASDAQ:TPST): Profit margin
Jun 2023 0 -7.58M
Sep 2023 0 -6.78M
Dec 2023 0 -7.48M
Mar 2024 0 -7.90M
Tempest Therapeutics, Inc. (NASDAQ:TPST): Analyst Estimates
Sep 2025 0 -12.51M
Oct 2025 0 -13.01M
Dec 2025 0 -14.18M
Mar 2026 0 -18.81M
  • Analysts Price target

  • Financials & Ratios estimates

Tempest Therapeutics, Inc. (NASDAQ:TPST): Debt to assets
Jun 2023 30742000 25.73M 83.7%
Sep 2023 23987000 25.17M 104.96%
Dec 2023 51603000 24.83M 48.13%
Mar 2024 44378000 23.74M 53.51%
Tempest Therapeutics, Inc. (NASDAQ:TPST): Cash Flow
Jun 2023 -6.39M -117K 1.18M
Sep 2023 -6.48M 0 21K
Dec 2023 -6.17M -7K 34.34M
Mar 2024 -7.18M -168K 450K

Tempest Therapeutics alternative data

Tempest Therapeutics, Inc. (NASDAQ:TPST): Employee count
Aug 2023 19
Sep 2023 19
Oct 2023 19
Nov 2023 19
Dec 2023 19
Jan 2024 19
Feb 2024 19
Mar 2024 17
Apr 2024 17
May 2024 17
Jun 2024 17
Jul 2024 17

Tempest Therapeutics other data

7.76% -14.74%
of TPST is owned by hedge funds
896.18K -2.17M
shares is hold by hedge funds

Tempest Therapeutics, Inc. (NASDAQ:TPST): Insider trades (number of shares)
Period Buy Sel
Jan 2022 3700 0
Apr 2022 2118644 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
WOIWODE THOMAS director, 10 percent owner
Common Stock 2,118,644 $2.36 $5,000,000
Purchase
DUBENSKY THOMAS W. director, officer: President
Common Stock 2,000 $4.78 $9,560
Purchase
WHITING SAMUEL officer: Chief Medical Officer
Common Stock 1,700 $4.81 $8,168
Friday, 6 December 2024
globenewswire.com
Monday, 25 November 2024
globenewswire.com
Tuesday, 12 November 2024
globenewswire.com
Thursday, 10 October 2024
benzinga.com
globenewswire.com
Friday, 20 September 2024
globenewswire.com
Thursday, 5 September 2024
globenewswire.com
Friday, 23 August 2024
globenewswire.com
Thursday, 15 August 2024
globenewswire.com
Thursday, 8 August 2024
globenewswire.com
Thursday, 20 June 2024
benzinga.com
investorplace.com
Tuesday, 18 June 2024
globenewswire.com
Friday, 7 June 2024
globenewswire.com
Friday, 31 May 2024
businesswire.com
Thursday, 9 May 2024
globenewswire.com
Friday, 26 April 2024
globenewswire.com
Wednesday, 17 April 2024
Seeking Alpha
Tuesday, 17 October 2023
MarketBeat
Friday, 13 October 2023
Market Watch
Thursday, 12 October 2023
Market Watch
Zacks Investment Research
Invezz
Wednesday, 11 October 2023
InvestorPlace
InvestorPlace
Market Watch
InvestorPlace
Tuesday, 10 October 2023
GlobeNewsWire
Tuesday, 15 August 2023
Zacks Investment Research
Wednesday, 31 May 2023
GlobeNewsWire
  • What's the price of Tempest Therapeutics stock today?

    One share of Tempest Therapeutics stock can currently be purchased for approximately $9.17.

  • When is Tempest Therapeutics's next earnings date?

    Unfortunately, Tempest Therapeutics's (TPST) next earnings date is currently unknown.

  • Does Tempest Therapeutics pay dividends?

    No, Tempest Therapeutics does not pay dividends.

  • How much money does Tempest Therapeutics make?

    Tempest Therapeutics has a market capitalization of 33.42M.

  • What is Tempest Therapeutics's stock symbol?

    Tempest Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "TPST".

  • What is Tempest Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Tempest Therapeutics?

    Shares of Tempest Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Tempest Therapeutics have?

    As Jul 2024, Tempest Therapeutics employs 17 workers.

  • When Tempest Therapeutics went public?

    Tempest Therapeutics, Inc. is publicly traded company for more then 12 years since IPO on 12 Nov 2012.

  • What is Tempest Therapeutics's official website?

    The official website for Tempest Therapeutics is tempesttx.com.

  • Where are Tempest Therapeutics's headquarters?

    Tempest Therapeutics is headquartered at 7000 Shoreline Court, South San Francisco, CA.

  • How can i contact Tempest Therapeutics?

    Tempest Therapeutics's mailing address is 7000 Shoreline Court, South San Francisco, CA and company can be reached via phone at +41 57988589.

Tempest Therapeutics company profile:

Tempest Therapeutics, Inc.

tempesttx.com
Exchange:

NASDAQ

Full time employees:

17

Industry:

Biotechnology

Sector:

Healthcare

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

7000 Shoreline Court
South San Francisco, CA 94080

CIK: 0001544227
ISIN: US87978U1088
CUSIP: 87978U108